Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment
- PMID: 19385710
- DOI: 10.2165/00003088-200948030-00003
Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment
Abstract
Background: Ovarian cancer is the leading cause of gynaecological cancer-related death in Western countries. Intraperitoneal (IP) peroperative chemotherapy is an interesting therapeutic option. However, very few data are available regarding pharmacokinetics and especially population pharmacokinetics.
Patients and methods: Thirty-one patients with advanced epithelial cancer classified as International Federation of Gynecology and Obstetrics stage IIIC were included in the study. Blood and IP samples were taken over a 24-hour period during and after IP treatment. Both total and ultrafiltered (Uf) platinum (Pt) concentrations were analysed using a population approach with nonlinear mixed-effects modelling (NONMEM) software. Improvement of the model with covariates was performed as well as assessment of the model using bootstrap and posterior visual predictive methods.
Results: Both IP fluid and serum pharmacokinetics were satisfactorily described with a three-compartment model for both Uf Pt and total Pt concentrations. The covariates were bodyweight for the IP volume of distribution in the Uf Pt model, and both IP and serum protein concentrations for the clearance from the central compartment in the total Pt model. A nomogram, based on the results of the Monte Carlo simulations, displays a dose recommendation regarding both the risk of renal toxicity and the potent efficacy of the treatment. A limited sampling strategy (LSS) allowing the estimation of potential risk of renal toxicity is also described.
Conclusion: The pharmacokinetics of cisplatin during peroperative IP chemotherapy could be successfully fitted with the present model, which allowed a dosing strategy accompanied by an LSS to facilitate the follow-up of patients.
Comment in
-
Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration.Clin Pharmacokinet. 2009;48(10):685-6; author reply 686-7. doi: 10.2165/11317280-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19757548 No abstract available.
Similar articles
-
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study.Br J Cancer. 2012 Jan 31;106(3):460-7. doi: 10.1038/bjc.2011.557. Epub 2011 Dec 15. Br J Cancer. 2012. PMID: 22173671 Free PMC article.
-
Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.Cancer Chemother Pharmacol. 2008 Mar;61(3):415-21. doi: 10.1007/s00280-007-0484-x. Epub 2007 May 15. Cancer Chemother Pharmacol. 2008. PMID: 17503047
-
Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding.Anticancer Drugs. 2005 Oct;16(9):1009-16. doi: 10.1097/01.cad.0000176505.94175.d4. Anticancer Drugs. 2005. PMID: 16162978 Clinical Trial.
-
Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.Arch Gynecol Obstet. 2014 Sep;290(3):425-34. doi: 10.1007/s00404-014-3252-2. Epub 2014 May 21. Arch Gynecol Obstet. 2014. PMID: 24845970 Review.
-
Clinical pharmacokinetics and dose optimisation of carboplatin.Clin Pharmacokinet. 1997 Sep;33(3):161-83. doi: 10.2165/00003088-199733030-00002. Clin Pharmacokinet. 1997. PMID: 9314610 Review.
Cited by
-
Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.Br J Cancer. 2010 Mar 2;102(5):827-32. doi: 10.1038/sj.bjc.6605560. Epub 2010 Feb 16. Br J Cancer. 2010. PMID: 20160731 Free PMC article.
-
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study.Br J Cancer. 2012 Jan 31;106(3):460-7. doi: 10.1038/bjc.2011.557. Epub 2011 Dec 15. Br J Cancer. 2012. PMID: 22173671 Free PMC article.
-
Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration.Clin Pharmacokinet. 2009;48(10):685-6; author reply 686-7. doi: 10.2165/11317280-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19757548 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical